Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.
Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160 mg i.m. every 4 weeks (n = 4) or 160 mg i.m. every 2 weeks (n = 6). Two patients had stabl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group|1
1998
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062954/ |